Oncology Drug Reference Sheet: Niraparib
Chelsea Backler MSN, APRN, AGCNS-BC, AOCNS®
Voice
Description
Niraparib (Zejula®) was approved in October 2019 for patients with homologous recombination deficiency (HRD)-positive advanced ovarian, fallopian tube, or primary peritoneal cancer.
ONS Drug Education
Short summaries of newly approved oncology-related therapies or drugs with new indications.
View All Drug Education